• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Citi Trends Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

    3/21/23 12:53:12 PM ET
    $AG
    $ALLR
    $ALT
    $ATNX
    Precious Metals
    Basic Materials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AG alert in real time by email

    Gainers

    • U.S. Xpress Enterprises, Inc. (NYSE:USX) shares surged 298% to $5.97 after Knight-Swift Transportation agreed to acquire the company for $6.15 per share.
    • Impac Mortgage Holdings, Inc. (NYSE:IMH) gained 94.8% to $0.39. Impac Mortgage Holdings recently posted a Q4 adjusted loss of $0.35 per share.
    • Cerberus Cyber Sentinel Corporation (NASDAQ:CISO) shares jumped 84.6% to $0.4245. Cerberus Cyber Sentinel said it sees Q4 revenue of $14.7 million and sees FY22 revenue of $46.5 million.
    • Quince Therapeutics, Inc. (NASDAQ:QNCX) gained 74.7% to $1.4708 after Echo Lake Capital offered to acquire the company for $1.60 per share in cash.
    • Pear Therapeutics, Inc.. (NASDAQ:PEAR) climbed 39.3% to $0.2919 after dropping 46% on Monday. Pear Therapeutics, last week, said it is exploring strategic alternatives and said it may seek a reorganization if it is unable to complete a transaction.
    • First Republic Bank (NYSE:FRC) shares climbed 29.7% to $15.80 following reports suggesting JP Morgan CEO Jamie Dimon is leading discussions to come up with a new rescue plan for the bank. Also, Treasury Secretary Yellen said the government is prepared to take more action to aid banks, which could be positively impacting the stock.
    • On Holding AG (NYSE:ONON) gained 29.1% to $27.85 after the company reported fourth-quarter FY22 sales growth of 91.9% year-on-year to CHF 366.8 million.
    • Novo Integrated Sciences, Inc. (NASDAQ:NVOS) jumped 23.7% to $0.1255.
    • Torrid Holdings Inc. (NYSE:CURV) surged 22.8% to $2.7385.
    • EZGO Technologies Ltd. (NASDAQ:EZGO) jumped 22% to $1.23.
    • Blue Star Foods Corp. (NASDAQ:BSFC) rose 21.6% to $0.1930.
    • So-Young International Inc. (NASDAQ:SY) gained 20.6% to $1.99 following Q4 results.
    • ImmunityBio, Inc. (NASDAQ:IBRX) gained 20% to $1.62.
    • Novo Integrated Sciences, Inc. (NASDAQ:NVOS) shares rose 19.5% to $0.1213.
    • Qualigen Therapeutics, Inc. (NASDAQ:QLGN) jumped 18.3% to $1.16 after the company announced the USPTO granted it patent number 11,560,380 for QN-302, its lead oncology investigational drug candidate.
    • Blue Star Foods Corp. (NASDAQ:BSFC) gained 18.3% to $0.1879 after jumping around 22% on Monday.
    • CURO Group Holdings Corp. (NYSE:CURO) rose 18% to $1.6750.
    • Qwest Corp. NT (NYSE:CTBB) gained 18% to $12.04.
    • Oportun Financial Corporation (NASDAQ:OPRT) shares climbed 17.7% to $3.99.
    • Sunlight Financial Holdings Inc. (NYSE:SUNL) climbed 16.1% to $0.3525.
    • Bird Global, Inc. (NYSE:BRDS) gained 13.9% to $0.1257 after declining 8% on Monday. Bird Global recently reported better-than-expected Q4 sales results.
    • Select Energy Services, Inc. (NASDAQ:WTTR) jumped 12.5% to $6.30. Select Energy Services announced a $50 million buyback program.
    • Canadian Solar Inc. (NASDAQ:CSIQ) surged 12.7% to $40.41 after the company reported better-than-expected Q4 results.
    • PacWest Bancorp (NASDAQ:PACW) gained 12.7% to $11.58.
    • Puyi Inc. (NASDAQ:PUYI) jumped 11.8% to $7.17. Puyi posted a narrower H1 loss.
    • Semantix, Inc. (NASDAQ:STIX) gained 8.3% to $4.2001.

    Losers

    • Qutoutiao Inc. (NASDAQ:QTT) fell 59.2% to $0.2850 after gaining 3% on Monday.
    • Altimmune, Inc. (NASDAQ:ALT) shares dropped 54% to $5.01 after the company announced results from the week 24 interim analysis of pemvidutide MOMENTUM Phase 2 obesity trial and 12-week Phase 1b type 2 diabetes safety trial.
    • Check-Cap Ltd. (NASDAQ:CHEK) fell 42.2% to $1.7501. Check-Cap said it 'plans to continue conducting its calibration studies, albeit at a slower pace, to collect additional clinical data and the company is also implementing a cost reduction plan, in order to extend its cash runway.'
    • Maxpro Capital Acquisition Corp. (NASDAQ:JMAC) dropped 26% to $9.09.
    • First Majestic Silver Corp. (NYSE:AG) fell 24.5% to $5.61 after the company temporarily suspended mining activities and reduced its workforce at Jerritt Canyon, which represented 21% of the company's 2022 revenue.
    • Jeffs' Brands Ltd (NASDAQ:JFBR) fell 22.6% to $1.03. Jeffs' Brands recently entered into a definitive agreement to acquire the entire share capital of Fort Products Ltd for $1.92 million.
    • YS Biopharma Co., Ltd. (NASDAQ:YS) dropped 22% to $10.14.
    • SigmaTron International, Inc. (NASDAQ:SGMA) dropped 21.4% to $2.46.
    • Allarity Therapeutics, Inc. (NASDAQ:ALLR) shares fell 21.4% to $0.1130. Allarity Therapeutics shares jumped 37% on Monday after the company said it dosed the first patient in its trial studying advanced solid tumors.
    • Athenex, Inc. (NASDAQ:ATNX) dropped 19.3% to $1.0168. Ladenburg Thalmann downgraded Athenex from Buy to Neutral.
    • Gelesis Holdings, Inc. (NASDAQ:GLS) shares fell 19% to $0.1701 after jumping over 90% on Monday.
    • HUB Cyber Security (Israel) Ltd. (NASDAQ:HUBC) dropped 19% to $1.79.
    • Bluejay Diagnostics, Inc. (NASDAQ:BJDX) fell 18% to $0.4411. Bluejay Diagnostics posted a FY22 loss of $0.46 per share.
    • HUYA Inc. (NYSE:HUYA) dropped 16.7% to $3.2650 after the company reported mixed Q4 financial results.
    • Connect Biopharma Holdings Limited (NASDAQ:CNTB) fell 15.9% to $1.11 after gaining 20% on Monday. Connect Biopharma announced post hoc data analysis from the Phase 2b CBP-201 global trial in moderate-to-severe atopic dermatitis (AD).
    • Citi Trends, Inc. (NASDAQ:CTRN) dropped 14.4% to $19.95 after the company reported Q4 financial results.
    • Boxed, Inc. (NYSE:BOXD) fell 14.3% to $0.1175 after jumping over 35% on Monday.
    • Tencent Music Entertainment Group (NYSE:TME) dropped 11.7% to $6.93 after the company reported Q4 financial results.
    • Roivant Sciences Ltd. (NASDAQ:ROIV) fell 11% to $7.75.
    • Viking Therapeutics, Inc. (NASDAQ:VKTX) declined 9.3% to $10.55.
    • GeneDx Holdings Corp. (NASDAQ:WGS) dropped 9.2% to $0.4581.
    • Karuna Therapeutics, Inc. (NASDAQ:KRTX) fell 8.5% to $166.76 after the company announced a $400 million offering of common stock.

    Now Read This: Wall Street's Most Accurate Analysts Say Hold These 3 Consumer Stocks With Over 5% Dividend Yields

    Get the next $AG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AG
    $ALLR
    $ALT
    $ATNX

    CompanyDatePrice TargetRatingAnalyst
    Viking Therapeutics Inc.
    $VKTX
    3/26/2026Peer Perform
    Wolfe Research
    On Holding AG
    $ONON
    3/25/2026$65.00 → $60.00Outperform
    Telsey Advisory Group
    First Majestic Silver Corp.
    $AG
    3/24/2026Market Perform → Outperform
    BMO Capital Markets
    Roivant Sciences Ltd.
    $ROIV
    3/20/2026$35.00Outperform
    Bernstein
    Tencent Music Entertainment Group
    $TME
    3/19/2026Overweight → Equal-Weight
    Morgan Stanley
    Altimmune Inc.
    $ALT
    3/18/2026$12.00Buy
    Truist
    Tencent Music Entertainment Group
    $TME
    3/18/2026$12.00Buy → Hold
    Daiwa Securities
    Tencent Music Entertainment Group
    $TME
    3/18/2026$13.00Buy → Neutral
    UBS
    More analyst ratings

    $AG
    $ALLR
    $ALT
    $ATNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Weaver Gregory L bought $17,700 worth of shares (5,000 units at $3.54), increasing direct ownership by 22% to 28,078 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:05:04 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Durso Jerome Benedict bought $70,790 worth of shares (20,000 units at $3.54), increasing direct ownership by 160% to 32,500 units (SEC Form 4)

    4 - Altimmune, Inc. (0001326190) (Issuer)

    3/9/26 7:00:05 AM ET
    $ALT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Meister Keith A. bought $13,460,090 worth of shares (169,521 units at $79.40) (SEC Form 4)

    4 - GeneDx Holdings Corp. (0001818331) (Issuer)

    3/5/26 7:19:34 PM ET
    $WGS
    Retail: Computer Software & Peripheral Equipment
    Technology

    $AG
    $ALLR
    $ALT
    $ATNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Jeffs' Brands Announces Corporate Name Change to Nexera Technologies and New Nasdaq Ticker Symbol "NEXR"

    Tel Aviv, Israel, March 30, 2026 (GLOBE NEWSWIRE) -- Jeffs' Brands Ltd ("Jeffs' Brands" or the "Company") (NASDAQ:JFBR, JFBRW)) today announced that effective as of March 26, 2026, it has officially changed its corporate name to Nexera Technologies Ltd. ("Nexera"), reflecting the Company's strategic shift toward advanced technologies and homeland security solutions. It is expected that effective March 31, 2026, the Company's ordinary shares will begin trading on the Nasdaq Capital Market under the new ticker symbol "NEXR", replacing the previous ticker "JFBR." The Company's warrants are expected to trade under the symbol "NEXRW," replacing the previous ticker "JFBRW." The corporate name

    3/30/26 8:55:00 AM ET
    $JFBR
    Other Specialty Stores
    Consumer Discretionary

    Quince Therapeutics Settles Approximately $16.4 Million of Debt

    Quince Therapeutics, Inc. (NASDAQ:QNCX) today announced the successful settlement of the company's outstanding obligations under its loan from the European Investment Bank (EIB) for a payment of $5.5 million. This marks a material milestone for Quince as the completion of the settlement resolves critical debt obligations and allows the company to advance its restructuring and evaluation of strategic alternatives aimed at maximizing shareholder value. Effective immediately upon the $5.5 million payment, Quince settled outstanding EIB debt obligations of approximately $16.4 million as of March 27, 2026. As a direct result of this $5.5 million payment, all of the company's obligations under

    3/30/26 8:30:00 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Connect Biopharma Announces $20.2 Million Private Placement Financing

    Funding from new and existing investors extends anticipated cash runway into the second half of 2027 SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma," "Connect" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 6,130,000 shares of its ordinary shares in a private placement at a price of $3.25 per share with respect to any purchaser that is not owned or controlled by an individual who is an officer, dir

    3/30/26 7:02:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AG
    $ALLR
    $ALT
    $ATNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Viking Therapeutics

    Wolfe Research initiated coverage of Viking Therapeutics with a rating of Peer Perform

    3/26/26 9:00:52 AM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Telsey Advisory Group reiterated coverage on On with a new price target

    Telsey Advisory Group reiterated coverage of On with a rating of Outperform and set a new price target of $60.00 from $65.00 previously

    3/25/26 10:11:48 AM ET
    $ONON
    Shoe Manufacturing
    Consumer Discretionary

    First Majestic Silver upgraded by BMO Capital Markets

    BMO Capital Markets upgraded First Majestic Silver from Market Perform to Outperform

    3/24/26 8:26:58 AM ET
    $AG
    Precious Metals
    Basic Materials

    $AG
    $ALLR
    $ALT
    $ATNX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for FAMOTIDINE issued to ATHENEX INC

    Submission status for ATHENEX INC's drug FAMOTIDINE (SUPPL-13) with active ingredient FAMOTIDINE has changed to 'Approval' on 01/07/2022. Application Category: ANDA, Application Number: 075684, Application Classification: Labeling

    1/12/22 4:41:30 AM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for KLISYRI

    Submission status for ATHENEX INC's drug KLISYRI (ORIG-1) with active ingredient TIRBANIBULIN has changed to 'Approval' on 12/14/2020. Application Category: NDA, Application Number: 213189, Application Classification: Type 1 - New Molecular Entity

    12/20/20 4:30:55 PM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AG
    $ALLR
    $ALT
    $ATNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Dempsey Paula

    4 - Torrid Holdings Inc. (0001792781) (Issuer)

    3/27/26 4:03:29 PM ET
    $CURV
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    SEC Form 4 filed by Park Hyon C.

    4 - Torrid Holdings Inc. (0001792781) (Issuer)

    3/27/26 4:03:19 PM ET
    $CURV
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    SEC Form 4 filed by Harper Lisa M

    4 - Torrid Holdings Inc. (0001792781) (Issuer)

    3/27/26 4:03:00 PM ET
    $CURV
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    $AG
    $ALLR
    $ALT
    $ATNX
    SEC Filings

    View All

    Quince Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

    3/30/26 8:35:07 AM ET
    $QNCX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Connect Biopharma Holdings Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Connect Biopharma Holdings Ltd (0001835268) (Filer)

    3/30/26 7:06:04 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Viking Therapeutics Inc.

    SCHEDULE 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)

    3/27/26 1:53:02 PM ET
    $VKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AG
    $ALLR
    $ALT
    $ATNX
    Leadership Updates

    Live Leadership Updates

    View All

    CISO Global Appoints Dhaval Damania as EVP of Cybersecurity & IT

    Experienced AI and enterprise IT operations leader joins Company to accelerate scalable growth, strengthen security architecture, and advance next-generation cyber software innovation Scottsdale, Ariz., Feb. 23, 2026 (GLOBE NEWSWIRE) -- CISO Global, Inc. (NASDAQ:CISO) ("CISO Global" or the "Company"), a provider of AI-powered cybersecurity software and compliance services, today announced the appointment of Dhaval Damania as Executive Vice President of Cybersecurity & IT. This appointment reinforces its continued commitment to operational excellence, innovation, and scalable growth across its next-generation cybersecurity software portfolio. In this role, Damania will lead CISO Global's

    2/23/26 8:30:00 AM ET
    $CISO
    Professional Services
    Consumer Discretionary

    Citi Trends, Inc. Announces Board Transition, Finance Committee Leadership Update, and Extension of Cooperation Agreement with Fund 1

    Citi Trends, Inc. (NASDAQ:CTRN) ("CITITRENDS" or the "Company"), a leading off-price value retailer of apparel, accessories and home trends primarily for Black families in the United States, today announced a series of governance and shareholder-related updates, including a Board transition, Finance Committee leadership change, and the extension of its cooperation agreement with Fund 1 Investments, LLC ("Fund 1"). The Company announced that Wes Calvert has departed from the Company's Board of Directors effective February 19, 2026, following his distinguished service on the Board, including his role as Chair of the Finance Committee. Concurrently, the Board has appointed Benjamin Faw as a

    2/20/26 6:45:00 AM ET
    $CTRN
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    CISO Global Lands 30 Year Sales Veteran Michael Czerneda to Ignite the Next Wave of Software Growth

    New Vice President of Sales to accelerate software-driven growth across cyber services platform and insurance distribution channels  Scottsdale, Ariz., Feb. 18, 2026 (GLOBE NEWSWIRE) -- CISO Global, Inc. (NASDAQ:CISO) ("CISO Global" or the "Company"), a provider of AI-powered cybersecurity software and compliance services, today announced the appointment of Michael Czerneda as Vice President of Sales. In this role, Czerneda will lead enterprise-wide sales initiatives as the Company accelerates its transition toward scalable, software-driven growth built on its established cyber services platform.  Czerneda brings more than 30 years of sales leadership experience spanning UCaaS, CCaaS, da

    2/18/26 8:30:00 AM ET
    $CISO
    Professional Services
    Consumer Discretionary

    $AG
    $ALLR
    $ALT
    $ATNX
    Financials

    Live finance-specific insights

    View All

    Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

    – Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, with near‑maximal responses achieved in ~90% of patients – – Rademikibart was well tolerated with safety comparable to placebo – – Data presented during late-breaking oral presentation at 2026 American Academy of Dermatology Annual Meeting –  – Company to host conference call and webcast today, March 30, 2026 at 8:00 a.m. ET – SAN DIEGO, March 30, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today anno

    3/30/26 7:01:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD

    – Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pulmonary disease (COPD) patients produced rapid improvement in FEV1 with many patients experiencing improvements in airway function of ≥200 mL as early as 15 minutes post-dosing – – The rapid improvement in FEV1 demonstrated with IV rademikibart in this study provides clinical confirmation of preclinical observations that rademikibart has a unique beneficial effect on bronchodilation – – Mean FEV1 improvements of ~200 - 400 mL were maintained through Day 29 in asthma and COPD patients – – Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD;

    3/30/26 7:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    So-Young Reports Unaudited Fourth Quarter and Fiscal Year 2025 Financial Results

    BEIJING, March 25, 2026 /PRNewswire/ -- So-Young International Inc. (NASDAQ:SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial HighlightsTotal revenues were RMB460.7 million (US$65.9 million[1]), compared with RMB369.2 million in the corresponding period of 2024. The aesthetic treatment services revenues were RMB248.1 million (US$35.5 million), compared with RMB81.3 million in the corresponding period of 2024, exceeding the high end of guidance.Net loss

    3/25/26 5:15:00 AM ET
    $SY
    EDP Services
    Technology

    $AG
    $ALLR
    $ALT
    $ATNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Torrid Holdings Inc.

    SC 13G - Torrid Holdings Inc. (0001792781) (Subject)

    12/12/24 6:06:52 PM ET
    $CURV
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Citi Trends Inc.

    SC 13G/A - Citi Trends Inc (0001318484) (Subject)

    12/6/24 4:29:10 PM ET
    $CTRN
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Citi Trends Inc.

    SC 13G/A - Citi Trends Inc (0001318484) (Subject)

    12/6/24 4:22:55 PM ET
    $CTRN
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary